Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Eribulin Proves Noninferior to Taxane as Combination Partner With Trastuzumab and Pertuzumab in HER2+ Breast Cancer

February 6th 2025

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer

February 5th 2025

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

Secondary Primary Cancer Prevention Strategies Following CAR T-Cell Therapy Are Underway

February 4th 2025

Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP.

A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care

February 3rd 2025

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

CAR T-Cell Therapy Results in Secondary Primary Cancers in Approximately 4% of Patients

January 31st 2025

Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP, detail the pathobiology of SPCs after CAR T-cell therapy and findings from a review on the cancers.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

January 30th 2025

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes

January 30th 2025

OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.

MB-105 Receives Orphan Drug Designation in Relapsed/Refractory CD5+ T-Cell Lymphoma

January 30th 2025

The FDA has granted orphan drug designation to the CAR T-cell therapy MB-105 in CD5-positive T-cell lymphoma.

Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies

January 29th 2025

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC

January 29th 2025

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC

January 28th 2025

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.

Encorafenib Combination Approval Paves the Way Forward in BRAF V600E–Mutated CRC

January 27th 2025

E. Gabriela Chiorean, MD, FASCO, highlights the significance of encorafenib plus cetuximab and mFOLFOX6’s FDA approval in BRAF V600E-mutated metastatic CRC.

Cabozantinib Bests Placebo in Extrapancreatic NETs With Primary Tumor Arising in the Gl Tract

January 24th 2025

A subgroup analysis of the CABINET trial showed that cabozantinib extended PFS vs placebo in extrapancreatic NETs with a primary tumor arising in the GI tract.

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

January 23rd 2025

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer

January 21st 2025

E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.

ACS Annual Report Shows Cancer Incidence Rates Are Rising in Select Populations

January 21st 2025

The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

January 21st 2025

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

January 16th 2025

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers

January 15th 2025

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.